Support For Serdolect In Specific Patients, But Panel Can’t Define Population
Executive Summary
The only way Lundbeck's schizophrenia drug might make it to market is if the sponsor and FDA can find a population where the benefits merit the cardiovascular risk and come up with a way to manage that risk. But it's more complicated than meets the eye, and not necessarily something a Risk Evaluation and Mitigation Strategy can handle